Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple MyelomaDecember 12, 2018
XPO1 inhibition restores the ability of intranuclear tumor suppressor genes to disrupt oncoproteins; it is emerging as a promising new investigational strategy in MM.
Investigators identify a novel role of the genes located on chr17p13 in the induction of apoptosis in multiple myeloma.
Continuous therapy appears to be the preferred treatment modality in newly diagnosed patients with multiple myeloma (MM).
The findings may support the triplet regimen as a new standard of care for these patients, according to Dr Facon.
BCMA expression did not correlate with clinical response.
A readout of results from a phase 1 trial featuring MCARH171 demonstrates the potential of the human-derived BCMA-targeted CAR-T for R/R MM.
CAR-T cells targeting CD19 and CD20 were successfully and reproducibly produced at the point-of-care within 14 days.
Patients saw a deepening of responses over time.
AMG 420 is an anti-B cell maturation antigen bispecific T cell engager antibody construct.
Early results of phase 1, dose-escalation trial demonstrate efficacy and safety of P-BCMA-101 CAR-T cell therapy in patients with R/R MM.
The investigational antibody construct exploits the power of native effector T cells, supporting antitumor activity shortly after administration.
Restricting MM cancer cells from making contact with the bone marrow microenvironment may be achieved through the delivery of inhibitors through nanoparticles.
The construct from Allogene has been engineered to avoid the serious immune-related complications linked to allogeneic transplantation.
Nizar Bahlis, MD, discusses his findings at the ASH 2018 meeting.
Habte Yimer, MD, discusses his findings at the ASH 2018 meeting.
Luspatercept Reduced RBC Transfusion Dependence in Lower-Risk Patients With Myelodysplastic SyndromesDecember 02, 2018
Findings from the MEDALIST trial revealed a significant reduction in transfusion burden for patients being treated with luspatercept compared with placebo
Sundar Jagannath, MD, discusses his findings at ASH 2018.
Robert Rifkin, MD, FACP, discusses the latest research being presented at ASH 2018.
Stringent CR criteria may not predict clinical outcomes for patients with MM.
Results of a comparison study, presented at ASH 2018, found that salvage HDCT followed by ASCT in patients with relapsed MM did not lead to significant difference in PFS or OS compared with continuous novel agent-based treatment.
A personalized prediction model for probability of survival in patients with MDS who undergo HCT is presented at the ASH 2018 Annual Meeting.
Rod A. Humerickhouse, MD, PhD, discusses phase 1, 2 findings on venetoclax for multiple myeloma.
Phase 1 results support further development.
Researchers also used the trial to collect more information on safety, patient‐reported outcomes, and a specific premedication treatment protocol.
Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.
By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.
Patients were randomly assigned to receive either daratumumab in combination with lenalidomide (an immunomodulatory drug) and dexamethasone (a corticosteroid) or lenalidomide and dexamethasone alone.
Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.
In select older patients, transplant improved survival outcomes compared with patients who did not receive autologous stem cell transplantation.
Although nearly half of patients had stable disease after study treatment, none of the patients achieved a very good partial response or a complete response.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?